ANDRIKOU, KALLIOPI
 Distribuzione geografica
Continente #
NA - Nord America 798
EU - Europa 368
AS - Asia 170
AF - Africa 50
SA - Sud America 9
Totale 1.395
Nazione #
US - Stati Uniti d'America 797
IT - Italia 83
SE - Svezia 80
SG - Singapore 67
UA - Ucraina 63
IE - Irlanda 49
CI - Costa d'Avorio 39
CN - Cina 39
DE - Germania 28
TR - Turchia 25
DK - Danimarca 24
FI - Finlandia 20
HK - Hong Kong 16
KR - Corea 14
MA - Marocco 8
BR - Brasile 7
FR - Francia 6
NL - Olanda 5
IN - India 4
BD - Bangladesh 3
DZ - Algeria 3
GB - Regno Unito 3
BE - Belgio 2
RU - Federazione Russa 2
VN - Vietnam 2
AR - Argentina 1
CA - Canada 1
CO - Colombia 1
CZ - Repubblica Ceca 1
GR - Grecia 1
RS - Serbia 1
Totale 1.395
Città #
Chandler 131
Jacksonville 64
Fairfield 53
Dublin 49
Ashburn 48
Boardman 46
Ann Arbor 40
Abidjan 39
New York 38
Wilmington 37
Seattle 33
Des Moines 28
Woodbridge 28
Cambridge 23
Singapore 23
Turin 19
Houston 18
Lawrence 17
Princeton 17
Hong Kong 16
San Mateo 13
Centro 12
Beijing 8
Helsinki 8
San Diego 6
Rome 5
Milan 4
Pune 4
Washington 4
Wuxi 4
Belo Horizonte 3
Dallas 3
Modena 3
Norwalk 3
Ancona 2
Brussels 2
Guangzhou 2
Hanoi 2
Isola della Scala 2
London 2
Los Angeles 2
Nanjing 2
Sassari 2
Wuhan 2
Amsterdam 1
Arcoverde 1
Ascoli Piceno 1
Betim 1
Bogotá 1
Campinas 1
Charata 1
Chicago 1
Dalian 1
Dhaka 1
Falls Church 1
Frankfurt (Oder) 1
Frankfurt am Main 1
Hounslow 1
Izmir 1
Jinan 1
Jinhua 1
Kolomna 1
Linyi 1
Macerata 1
Mafra 1
Mondolfo 1
Murmansk 1
Newark 1
Olomouc 1
Pescara 1
Qingdao 1
San Severino Marche 1
Santa Clara 1
Santa Maria a Monte 1
Seoul 1
Tiantai Chengguanzhen 1
Toronto 1
Torre Del Greco 1
Tétouan 1
Yiwu 1
Totale 903
Nome #
The role of Aspirin as antitumoral agent for heavily pre-treated metastatic colorectal cancer patients receiving capecitabine monotherapy. BMC Cancer 132
Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy 123
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 120
Lgr5 expression, cancer stem cells and pancreatic cancer: Results from biological and computational analyses 106
The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy 106
KRAS mutation status is associated with specific pattern of genes expression in pancreatic adenocarcinoma 94
Toll like receptors and pancreatic diseases: From a pathogenetic mechanism to a therapeutic target 93
HER family receptor expression and prognosis in pancreatic cancer 84
KRAS: To be or not to be targeted? Biologic and computational analyses in pancreatic adenocarcinoma 78
Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New 71
Panitumumab for the treatment of metastatic colorectal cancer: A review 71
Trattamento del carcinoma del pancreas. Attualità e prospettive 69
Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma 69
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 57
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 36
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 34
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 32
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 30
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 30
Totale 1.435
Categoria #
all - tutte 8.057
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.057


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202053 0 0 0 0 0 0 13 3 14 2 4 17
2020/2021258 17 21 29 3 17 15 20 16 24 54 32 10
2021/2022139 7 22 2 5 1 10 3 8 11 18 16 36
2022/2023392 24 53 28 29 26 66 1 16 94 6 38 11
2023/2024195 37 5 13 24 25 58 2 3 1 3 1 23
2024/2025193 74 30 8 10 27 26 18 0 0 0 0 0
Totale 1.435